Haematic antegrade repriming to enhance recovery after cardiac surgery from the perfusionist side

© The Author(s). This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/. This document is the Published version of a Published Work that appeared in final form in The Journal of extracorporeal Technology. To access the final edited and published work see https://doi.org/10.1051/ject/2023004New era of cardiac surgery aims to provide an enhanced postoperative recovery through the implementation of every step of the process. Thus, perfusion strategy should adopt evidence-based measures to reduce the impact of cardiopulmonary bypass (CPB). Hematic Antegrade Repriming (HAR) provides a standardized procedure combining several measures to reduce haemodilutional priming to 300 mL. Once the safety of the procedure in terms of embolic release has been proven, the evaluation of its beneficial effects in terms of transfusion and ICU stay should be assessed to determine if could be considered for inclusion in Enhanced Recovery After Cardiac Surgery (ERACS) programs. Methods: Two retrospective and non-randomized cohorts of high-risk patients, with similar characteristics, were assessed with a propensity score matching model. The treatment group (HG) (n = 225) received the HAR. A historical cohort, exposed to conventional priming with 1350 mL of crystalloid confirmed the control group (CG) (n = 210). Results: Exposure to any transfusion was lower in treated (66.75% vs. 6.88%, p 10 h) (26.51% vs. 12.62%; p 2 d) (47.47% vs. 31.19%; p < 0.01) were fewer for treated. HAR did not increase early morbidity and mortality. Related savings varied from 581 to 2741.94 $/patient, depending on if direct or global expenses were considered. Discussion: By reducing the gaseous and crystalloid emboli during CPB initiation, HAR seems to have a beneficial impact on recovery and reduces the overall transfusion until discharge, leading to significant cost savings per process. Due to the preliminary and retrospective nature of the research and its limitations, our findings should be validated by future prospective and randomized studie

Experience with an easy, fast and safe method for peripheral artery approach in minimally invasive cardiac surgery

© 2012 Sociedad Española de Cirugía Torácica-Cardiovascular. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Published version of a Published Work that appeared in final form in Cirugía Cardiovascular. To access the final edited and published work see https://doi.org/10.1016/j.circv.2013.09.010Objetivos Describir nuestra experiencia con una técnica de abordaje vascular periférico en procedimientos de cirugía cardiaca mínimamente invasiva (CCMI): Heart-Port® e implante valvular aórtico transfemoral (TAVI). Métodos Análisis en laboratorio experimental y práctica quirúrgica. Procedimiento: incisión en pliegue inguinal (3-4 cm). Exposición de vaso/s femoral/es sin disección ni loop vascular. En mitad superior del vaso, 2 puntos longitudinales, intramurales, en «U», apoyados a ambos lados del eje vascular. Canulación por técnica de Seldinger en punto medio del vaso, equidistante de ambos pares de parches. Decanulación por anudado alternativo. Resultados Ochenta y un pacientes sometidos a procedimientos de CCMI: 52 Heart-Port® y 29 TAVI-transfemoral. Mortalidad global precoz: 2 pacientes (TAVI), sin relación con complicaciones vasculares. Ausencia de morbilidad asociada al abordaje en el grupo de Heart-Port®. En TAVI: una disección focal iliaca, un hematoma retroperitoneal y un caso de linforrea, resueltos con tratamiento conservador. Ausencia de isquemia aguda/hematoma/seudoaneurisma/reparación quirúrgica o intravascular o limitación funcional basal. El análisis en laboratorio demostró efecto de bolsa de tabaco sólo en el sentido longitudinal, sin causar estenosis transversal. Conclusiones Este método de acceso arterial periférico puede ser aplicado a diferentes procedimientos de CCMI resultando simple (2 suturas y técnica Seldinger), reproducible, rápido (no requiere reconstrucción tras decanulación) y seguro (no requiere pinzado vascular, técnica Seldinger «a cielo abierto», baja tasa de complicaciones). -----------------Objectives To describe our experience with a technique for peripheral vascular approach in minimally invasive cardiac surgery (MICS): Heart-Port® and transfemoral aortic valve implantation (TAVI). Methods Experimental laboratory analysis and surgical practice. Procedure: groin incision (3-4 cm) for femoral vessels exposure, without dissection or vascular loops use. Placement of two longitudinal, intramural, “U” shaped, pledgeted stitches in the upper half of the vessel. Seldinger cannulation in the half point of the top of the vessel, between both pairs of pledgets. Decanulation by alternative knotting of the stitches. Results 81 patients undergoing MICS procedures: 52 Heart-Port® and 29 transfemoral-TAVI. Early mortality: 2 patients (TAVI) not related to vascular complications. Absence of morbidity related to vascular approach in Heart-Port® group. In TAVI group: one focal iliac dissection, one retroperitonal haematoma and one case of lymphorrea; managed by conservative treatment. Absence of acute ischaemia/haematoma/pseudoaneurysm/need of surgical or endovascular repair or functional limitation different from basal preoperative. Laboratory analysis showed only longitudinal purse-string effect, limiting transverse diameter stenosis. Conclusions This method for peripheral vascular approach can be applied in different MICS procedures resulting simple (2 stitches and Seldinger cannulation), reproducible, fast (does not require artery reconstruction after decannulation) and safe (does not require vascular clamp, “open-field” Seldinger technique, low rate of complications)

Technical failure in the implant of the Geoform® ring during an hyper-corrective annuloplasty: to purpose of a case

© 2013 Sociedad Española de Cirugía Torácica-Cardiovascular. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Published version of a Published Work that appeared in final form in Cirugía Cardiovascular. To access the final edited and published work see https://doi.org/10.1016/j.circv.2013.04.002La insuficiencia mitral funcional comúnmente va asociada a la miocardiopatía dilatada, y su corrección se basa habitualmente en realizar una anuloplastia mediante el implante de un anillo rígido. Presentamos un caso de insuficiencia mitral severa en el contexto de una miocardiopatía dilatada que fue corregida mediante el implante de un anillo Geoform® con buen resultado postoperatorio inmediato pero con fracaso tardío de la técnica por dehiscencia de la prótesis anular y fallo de la anuloplastia que obligó a una reintervención e implante de una prótesis valvular mecánica para la solución definitiva del problema.--------------------------Functional mitral regurgitation often is associated with dilated cardiomyopathy, or left ventricular remodeling. Surgical repair result commonly in an annuloplasty ring. We present a case of severe mitral regurgitation due to dilated cardiomyopathy treated with implant of Geoform® annuloplasty ring, with a good immediate outcome, and a successive failure of the annuloplasty due to dehiscence of the ring and requirement of a mitral valve replacement

TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression

In triple-negative breast cancer (TNBC), the pleiotropic NDRG1 (N-Myc downstream regulated gene 1) promotes progression and worse survival, yet contradictory results were documented, and the mechanisms remain unknown. Phosphorylation and localization could drive NDRG1 pleiotropy, nonetheless, their role in TNBC progression and clinical outcome was not investigated. We found enhanced p-NDRG1 (Thr346) by TGFβ1 and explored whether it drives NDRG1 pleiotropy and TNBC progression. In tissue microarrays of 81 TNBC patients, we identified that staining and localization of NDRG1 and p-NDRG1 (Thr346) are biomarkers and risk factors associated with shorter overall survival. We found that TGFβ1 leads NDRG1, downstream of GSK3β, and upstream of NF-κB, to differentially regulate migration, invasion, epithelial-mesenchymal transition, tumor initiation, and maintenance of different populations of cancer stem cells (CSCs), depending on the progression stage of tumor cells, and the combination of TGFβ and GSK3β inhibitors impaired CSCs. The present study revealed the striking importance to assess both total NDRG1 and p-NDRG1 (Thr346) positiveness and subcellular localization to evaluate patient prognosis and their stratification. NDRG1 pleiotropy is driven by TGFβ to differentially promote metastasis and/or maintenance of CSCs at different stages of tumor progression, which could be abrogated by the inhibition of TGFβ and GSK3β.Instituto de Salud Carlos III European Commission PI15/00336 PI19/01533 CP14/00197 CP19/00029 PIE16/00045Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government RTI2018.101309B-C22Chair "Doctors Galera-Requena in cancer stem cell research" CMC-CTS963European Regional Development Fund (European Union)Ministerio de Universidades FPU19/04450Junta de Andalucia RH-0139-2020Sistema Nacional de Garantia Juvenil (Fondo Social Europeo) 8064Junta de Andalucia, Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades DOC_01686Fundacion Cientifica Asociacion Espanola Contra el Cancer, Junta Provincial de Jaen (AECC) PRDJA19001BLA

Contact pathway in surgical and transcatheter aortic valve replacement

© 2022 de la Morena-Barrio, Corral, López-García, Jiménez-Díaz, Miñano, Juan-Salvadores, Esteve-Pastor, Baz-Alonso, Rubio, Sarabia-Tirado, García-Navarro, García-Lara, Marín, Vicente, Pinar, Cánovas and de la Morena. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0. This document is the Published version of a Published Work that appeared in final form in Frontiers in Cardiovascular Medicine. To access the final edited and published work see https://doi.org/10.3389/fcvm.2022.887664Background: Aortic valve replacement is the gold standard treatment for severe symptomatic aortic stenosis, but thrombosis of bioprosthetic valves (PVT) remains a concern. Objective: To analyze the factors involved in the contact pathway during aortic valve replacement and to assess their impact on the development of thromboembolic complications. Methods: The study was conducted in 232 consecutive patients who underwent: transcatheter aortic valve replacement (TAVR, N = 155), and surgical valve replacement (SAVR, N = 77) (MUVITAVI project). Demographic and clinical data, outcomes including a combined end point (CEP) of thrombotic events, and imaging controls were recruited. Samples were collected 24 h before and 48 h after valve replacement. FXII, FXI and (pre)kallikrein were evaluated by Western Blot and specific ELISA with nanobodies. Results: The CEP of thrombotic events was reached by 19 patients: 13 patients presented systemic embolic events and 6 patients subclinical PVT. Valve replacement did not cause FXII activation or generation of kallikrein. There was a significant reduction of FXI levels associated with the procedure, which was statistically more pronounced in SAVR than in TAVR. Cases with reductions of FXI below 80% of basal values had a lower incidence of embolic events during the procedure than patients in whom FXI increased above 150%: 2.7 vs. 16.7%; p: 0.04. Conclusion: TAVR or SAVR did not significantly activate the contact pathway. A significant reduction of FXI, was observed, particularly in SAVR, associated with lower incidence of thrombotic events. These results encourage evaluating the usefulness and safety of FXI-directed antithrombotic treatments in these patients

Effect of compost on Retama seeds germination

Comunicación oral presentada en: III congreso CAOS, Granada EEZ, España. 4 mayo 202

Impacto de la COVID-19 en los servicios de cirugía cardiovascular en España: Análisis de los grupos relacionados con el diagnóstico (Estudio SECCE-COVID-19 fase 2)

Introducción y objetivos La pandemia por COVID-19 causada por infección del virus SARS-CoV-2 ha saturado al sistema sanitario español, afectándose la atención de las enfermedades cardiovasculares. Queremos cuantificar el impacto de la pandemia en el número de las intervenciones quirúrgicas cardíacas analizando los grupos relacionados con el diagnóstico (GRD) más prevalentes de nuestra especialidad. Métodos A instancias de la Sociedad Española de Cirugía Cardiovascular y Endovascular, se solicitó a todos los centros nacionales que quisieron participar, los datos de los códigos de GRD números 162 (cirugía sobre válvulas cardíacas con infarto o diagnóstico complejo), 163 (cirugía sobre válvulas cardíacas sin infarto o diagnóstico complejo), 165 (bypass coronario con infarto o diagnóstico complejo), 166 (bypass coronario sin infarto o diagnóstico complejo) y 167 (otros procedimientos cardiotorácicos o vasculares torácicos) entre el 1 de marzo de 2020 y el 30 de septiembre de 2020 (siete meses), y como período control las mismas fechas de 2019. Resultados Se recibieron los datos de 24 hospitales, 22 públicos y dos privados. Existió un descenso global en el número de intervenciones del 30% (rango -19 a -42%, p < 0,001) de 4.648 en 2019 a 3.262 en 2020 (-1.386 de diferencia), siendo +7% para el GRD 162 (p = 0,500), -37% para el 163 (p = 0,001), -9% para el 165 (p = 0,304), -32% para el 166 (p = 0,001), y -16% para el 167 (p = 0,062). Conclusiones Existió un descenso global de cirugías estadísticamente significativo en 2020 del 30% respecto del 2019 entre el 1 de marzo y el 30 de septiembre

Seven years experience with rapid deployment Edwards Intuity aortic prosthesis

© 2020 Sociedad Española de Cirugía Cardiovascular y Endovascular. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Published version of a Published Work that appeared in final form in Cirugía Cardiovascular. To access the final edited and published work see https://doi.org/10.1016/j.circv.2020.08.002Introducción Las prótesis aorticas de rápido despliegue aparecieron hace 10 años para tratar la estenosis aórtica. El sistema de válvula Edwards Intuity es una prótesis biológica basada en la válvula Edwards Magna con un marco infraanular. Presentamos los resultados clínicos y hemodinámicos a corto y largo plazo obtenidos con esta prótesis biológica. Métodos Ciento diecisiete pacientes (65% varones, 75 ± 4,5 años) con estenosis aórtica (gradiente medio preoperatorio de 49,6 ± 12 mm Hg) recibieron una prótesis Edwards Intuity entre septiembre de 2012 y diciembre de 2019. Se incluyeron en una base de datos prospectiva que recogía diferentes variables. La media de seguimiento fue de 36 ± 21 meses. Resultados Mortalidad hospitalaria del 3,4%, supervivencia al año, a los 3 y 6 años del 95%, 90% y 81%, respectivamente. Se utilizó hemiesternotomía media superior en 78 pacientes (67%). La mediana de tiempos de isquemia miocárdica y de circulación extracorpórea de toda la serie fueron 40 (33-50) minutos y 59 (48-73) minutos. Gradientes medios al alta, al año y a los 2 años fueron 10 ± 4 mm, 9 ± 3,5 mm y 8,4 ± 3,4 mm Hg. Ocho pacientes (7%) necesitaron marcapasos en el postoperatorio. Dos pacientes (0,6%) se reintervinieron en seguimiento por endocarditis y otro (0,3%) se reintervino por fuga periprotésica. Conclusión El sistema de válvula Edwards Intuity presenta buenos resultados clínicos y hemodinámicos a corto y largo plazo. Estas prótesis aórticas se pueden considerar una alternativa a las prótesis convencionales, sobre todo en cirugía de mínimo acceso y en intervenciones complejas.----------------Introduction Rapid deployment aortic valves appeared ten years ago to treat aortic stenosis. The Edwards Intuity Valve System is a biological prosthesis based on the Edwards Magna valve with an infra-annular framework. We present the short and long-term clinical and hemodynamic results obtained with this biological prosthesis. Methods One hundred seventeen patients (65% male, 75 ± 4.5 years) with aortic stenosis (mean preoperative gradient of 49.6 ± 12 mm Hg) received an Edwards Intutiy prosthesis between September 2012 and December 2019. They were included in a prospective data base that collected different variables. The mean follow-up was 36 ± 21 months. Results Hospital mortality of 3.4%. Survival at one, three and six years of 95%, 90% and 81%, respectively. Upper hemisternotomy was used in 78 patients (67%). The median times of myocardial ischemia and extracorporeal circulation for the entire series were 40 (33-50) minutes and 59 (48-73) minutes. Average gradients at discharge, one year and two years were 10 ± 4 mm, 9 ± 3.5 mm and 8.4 ± 3.4 mm Hg. Eight patients (7%) required pacemakers in the postoperative period. Two patients (0.6%) underwent surgery for endocarditis and another (0.3%) underwent surgery for periprosthetic leak. Conclusion The Edwards Intutiy valve system presents good short and long term clinical and hemodynamic results. These aortic prostheses can be considered an alternative to conventional prostheses, especially in minimal access surgery and in complex interventions

Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy

Background Active targeting by surface-modified nanoplatforms enables a more precise and elevated accumulation of nanoparticles within the tumor, thereby enhancing drug delivery and efficacy for a successful cancer treatment. However, surface functionalization involves complex procedures that increase costs and timelines, presenting challenges for clinical implementation. Biomimetic nanoparticles (BNPs) have emerged as unique drug delivery platforms that overcome the limitations of actively targeted nanoparticles. Nevertheless, BNPs coated with unmodified cells show reduced functionalities such as specific tumor targeting, decreasing the therapeutic efficacy. Those challenges can be overcome by engineering non-patient-derived cells for BNP coating, but these are complex and cost-effective approaches that hinder their wider clinical application. Here we present an immune-driven strategy to improve nanotherapeutic delivery to tumors. Our unique perspective harnesses T-cell exhaustion and tumor immune evasion to develop a groundbreaking new class of BNPs crafted from exhausted T-cells (NExT) of triple-negative breast cancer (TNBC) patients by specific culture methods without sophisticated engineering. Methods NExT were generated by coating PLGA (poly(lactic-co-glycolic acid)) nanoparticles with TNBC-derived T-cells exhausted in vitro by acute activation. Physicochemical characterization of NExT was made by dynamic light scattering, electrophoretic light scattering and transmission electron microscopy, and preservation and orientation of immune checkpoint receptors by flow cytometry. The efficacy of chemotherapy-loaded NExT was assessed in TNBC cell lines in vitro. In vivo toxicity was made in CD1 mice. Biodistribution and therapeutic activity of NExT were determined in cell-line- and autologous patient-derived xenografts in immunodeficient mice. Results We report a cost-effective approach with a good performance that provides NExT naturally endowed with immune checkpoint receptors (PD1, LAG3, TIM3), augmenting specific tumor targeting by engaging cognate ligands, enhancing the therapeutic efficacy of chemotherapy, and disrupting the PD1/PDL1 axis in an immunotherapy-like way. Autologous patient-derived NExT revealed exceptional intratumor accumulation, heightened chemotherapeutic index and efficiency, and targeted the tumor stroma in a PDL1+ patient-derived xenograft model of triple-negative breast cancer. Conclusions These advantages underline the potential of autologous patient-derived NExT to revolutionize tailored adoptive cancer nanotherapy and chemoimmunotherapy, which endorses their widespread clinical application of autologous patient-derived NExT.This work was funded by Instituto de Salud Carlos III (grants PI19/01533, CP19/00029 to S.G.-P.), Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (grant P29/22/02 to S.G.-P.), by MCIN/AE (grant RTI2018.101309B-C22 and PID2022-140151OB-C22 funded by MCIN/AEI https://doi.org/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to J.A.M.), the Chair “Doctors Galera-Requena in cancer stem cell research” (CMC-CTS963 to J.A.M.), the European Regional Development Fund (European Union), Fundación Científica Asociación Española Contra el Cáncer, Junta Provincial de Jaén (AECC) (grant PRDJA19001BLAY to J.L.B.-C.,), Proyectos Intramurales ibs.GRANADA (grant INTRAIBS-2021-09 to C.G.-L.), Junta de Andalucía, Plan Andaluz de Investigación, Desarrollo e Innovación (grant POSTDOC_21_638 to C.G.-L.), Ministerio de Ciencia, Innovación y Universidades (grant FPU19/04450 to A.L.-T.), Junta de Andalucía, Consejería de Transformación Económica, Industria, Conocimiento y Universidades (grant DOC_01686 to J.C.).Peer reviewe